Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years.
Latest Information Update: 17 Jul 2023
At a glance
- Drugs GSK 692342 (Primary) ; AS02
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Feb 2011 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
- 09 Nov 2006 Status change
- 12 Dec 2005 New trial record.